71.35
price up icon0.88%   0.625
after-market アフターアワーズ: 71.35
loading
前日終値:
$70.72
開ける:
$71
24時間の取引高:
818.02K
Relative Volume:
0.77
時価総額:
$2.41B
収益:
$55.63M
当期純損益:
$-158.10M
株価収益率:
-8.4737
EPS:
-8.4202
ネットキャッシュフロー:
$-203.94M
1週間 パフォーマンス:
+10.04%
1か月 パフォーマンス:
+12.10%
6か月 パフォーマンス:
+87.62%
1年 パフォーマンス:
+185.40%
1日の値動き範囲:
Value
$69.67
$73.98
1週間の範囲:
Value
$64.24
$73.98
52週間の値動き範囲:
Value
$21.02
$109.00

Nektar Therapeutics Stock (NKTR) Company Profile

Name
名前
Nektar Therapeutics
Name
セクター
Healthcare (1074)
Name
電話
(415) 482-5300
Name
住所
455 MISSION BAY BOULEVARD SOUTH, SAN FRANCISCO, CA
Name
職員
63
Name
Twitter
@nektarnews
Name
次回の収益日
2026-08-06
Name
最新のSEC提出書
Name
NKTR's Discussions on Twitter

Compare NKTR vs VRTX, REGN, ARGX, RVMD, ALNY

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
NKTR icon
NKTR
Nektar Therapeutics
71.35 2.39B 55.63M -158.10M -203.94M -8.4202
VRTX icon
VRTX
Vertex Pharmaceuticals Inc
479.00 121.16B 12.34B 4.34B 3.71B 16.87
REGN icon
REGN
Regeneron Pharmaceuticals Inc
667.17 68.78B 14.92B 4.42B 3.79B 41.04
ARGX icon
ARGX
Argen X Se Adr
888.82 57.44B 4.16B 1.29B 734.26M 19.58
RVMD icon
RVMD
Revolution Medicines Inc
188.07 40.23B 742.00K -1.37B -1.07B -7.0731
ALNY icon
ALNY
Alnylam Pharmaceuticals Inc
278.40 36.28B 4.29B 577.22M 641.34M 4.2086

Nektar Therapeutics Stock (NKTR) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2026-03-24 開始されました Wedbush Neutral
2026-03-17 開始されました TD Cowen Buy
2026-02-10 アップグレード William Blair Mkt Perform → Outperform
2025-11-26 開始されました Citigroup Buy
2025-06-24 繰り返されました BTIG Research Buy
2025-06-24 繰り返されました H.C. Wainwright Buy
2025-04-11 アップグレード Jefferies Hold → Buy
2025-03-14 アップグレード Oppenheimer Perform → Outperform
2025-01-08 開始されました B. Riley Securities Buy
2024-12-10 開始されました H.C. Wainwright Buy
2024-11-04 開始されました Piper Sandler Overweight
2024-09-30 再開されました BTIG Research Buy
2024-06-28 開始されました Rodman & Renshaw Buy
2023-11-20 再開されました JP Morgan Underweight
2023-11-09 アップグレード TD Cowen Market Perform → Outperform
2023-05-10 アップグレード Jefferies Underperform → Hold
2023-02-24 ダウングレード Jefferies Hold → Underperform
2022-08-08 ダウングレード JP Morgan Neutral → Underweight
2022-05-31 再開されました Jefferies Hold
2022-04-18 ダウングレード Goldman Neutral → Sell
2022-03-15 ダウングレード Cowen Outperform → Market Perform
2022-03-15 ダウングレード Mizuho Buy → Neutral
2022-03-14 ダウングレード BTIG Research Buy → Neutral
2022-03-14 ダウングレード BofA Securities Neutral → Underperform
2022-03-14 ダウングレード Stifel Buy → Hold
2022-03-14 ダウングレード William Blair Outperform → Mkt Perform
2022-03-09 アップグレード Oppenheimer Perform → Outperform
2021-11-08 アップグレード The Benchmark Company Hold → Buy
2021-09-10 開始されました BofA Securities Neutral
2021-06-28 アップグレード Stifel Hold → Buy
2021-05-18 再開されました Goldman Neutral
2021-02-22 ダウングレード The Benchmark Company Buy → Hold
2021-01-06 開始されました Stifel Hold
2020-09-14 開始されました JP Morgan Neutral
2020-06-10 ダウングレード CFRA Hold → Sell
2020-05-12 繰り返されました H.C. Wainwright Neutral
2020-04-22 開始されました The Benchmark Company Buy
2020-03-30 アップグレード Goldman Sell → Neutral
2020-03-04 開始されました Barclays Overweight
2020-02-03 アップグレード Mizuho Neutral → Buy
2019-10-24 開始されました Oppenheimer Perform
2019-10-08 ダウングレード Goldman Buy → Sell
2019-08-09 ダウングレード JP Morgan Overweight → Neutral
2019-08-09 ダウングレード Jefferies Buy → Hold
2019-08-09 ダウングレード Mizuho Buy → Neutral
2019-03-15 開始されました SVB Leerink Mkt Perform
2018-12-13 開始されました Goldman Buy
2018-06-11 ダウングレード H.C. Wainwright Buy → Neutral
2018-06-04 繰り返されました H.C. Wainwright Buy
2018-04-20 開始されました Seaport Global Securities Buy
2018-04-13 再開されました Piper Jaffray Overweight
2018-04-06 繰り返されました Mizuho Buy
2018-04-02 再開されました H.C. Wainwright Buy
すべてを表示

Nektar Therapeutics (NKTR) 最新ニュース

pulisher
03:07 AM

Is Nektar Therapeutics (NKTR) Undervalued On Its Phase 3 Rezpegaldesleukin Launch? - simplywall.st

03:07 AM
pulisher
11:18 AM

Nektar: Sanofi’s Exit Clears A Competitor But Raises The Bar In Atopic Dermatitis (NKTR) - Seeking Alpha

11:18 AM
pulisher
03:28 AM

Nektar Therapeutics (NKTR) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey

03:28 AM
pulisher
Jul 26, 2026

Bronstein, Gewirtz & Grossman, LLC Is Investigating Nektar Therapeutics (NKTR) And Encourages Stockholders to Connect - ACCESS Newswire

Jul 26, 2026
pulisher
Jul 26, 2026

Nektar Therapeutics (NKTR) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey

Jul 26, 2026
pulisher
Jul 25, 2026

Nektar Therapeutics (NKTR) Financial Health: Profitability & Balance Sheet Analysis - TradingKey

Jul 25, 2026
pulisher
Jul 25, 2026

NKTR|Nektar Therapeutics|Price:70.004|Chg%:-0.721 - TradingKey

Jul 25, 2026
pulisher
Jul 25, 2026

Nektar Therapeutics (NKTR) Valuation: PE, PB & Fair Value Analysis - TradingKey

Jul 25, 2026
pulisher
Jul 24, 2026

Form 4 Nektar Therapeutics For: 24 July By Investing.com - Investing.com Nigeria

Jul 24, 2026
pulisher
Jul 24, 2026

Nektar Therapeutics (NKTR) CEO granted 57,200 options with $15.15 strike - Stock Titan

Jul 24, 2026
pulisher
Jul 24, 2026

Nektar Therapeutics Reports Vesting of 16,500 Stock Options for Chief R&D Officer Jonathan Zalevsky - Kalkine Media

Jul 24, 2026
pulisher
Jul 24, 2026

Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - TradingView

Jul 24, 2026
pulisher
Jul 24, 2026

Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - PR Newswire

Jul 24, 2026
pulisher
Jul 24, 2026

How Investors Are Reacting To Nektar Therapeutics (NKTR) Launching Global Phase 3 ZENITH AD Trials - simplywall.st

Jul 24, 2026
pulisher
Jul 24, 2026

ITH0.F interactive stock chart | Nektar Therapeutics R stock - Yahoo Finance UK

Jul 24, 2026
pulisher
Jul 24, 2026

Analysts Offer Insights on Healthcare Companies: Johnson & Johnson (JNJ), Helus Pharma (HELP) and Nektar Therapeutics (NKTR) - The Globe and Mail

Jul 24, 2026
pulisher
Jul 24, 2026

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Nektar Therapeutics (NKTR) and Encourages Shareholders to Learn More About the Investigation - ACCESS Newswire

Jul 24, 2026
pulisher
Jul 23, 2026

NKTR Stock Soars After Nektar Reports Positive Atopic Dermatitis Trial Results - Stocktwits

Jul 23, 2026
pulisher
Jul 23, 2026

symbol__ Stock Quote Price and Forecast - CNN

Jul 23, 2026
pulisher
Jul 23, 2026

NKTR|Nektar Therapeutics|Price:70.780|Chg%:+1.420 - TradingKey

Jul 23, 2026
pulisher
Jul 22, 2026

Nektar Therapeutics Initiated at Buy by Canaccord Genuity - Moomoo

Jul 22, 2026
pulisher
Jul 22, 2026

NKTR Up on Start of Phase III Program on Rezpeg for Atopic Dermatitis - Yahoo Finance

Jul 22, 2026
pulisher
Jul 22, 2026

Nektar Therapeutics (NKTR) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation - ACCESS Newswire

Jul 22, 2026
pulisher
Jul 22, 2026

Nektar (NKTR) Launches Global Trials for Novel Atopic Dermatitis Treatment - GuruFocus

Jul 22, 2026
pulisher
Jul 21, 2026

Nektar Therapeutics Starts Phase 3 ZENITH AD Program Evaluating Rezpegaldesleukin in Moderate-to-Severe AD - The Dermatology Digest

Jul 21, 2026
pulisher
Jul 21, 2026

Nektar Therapeutics Announces Start of Phase 3 ZENITH AD Program Evaluating Novel Regulatory T-Cell Biologic Rezpegaldesleukin in Moderate-to-Severe Atopic Dermatitis - PR Newswire

Jul 21, 2026
pulisher
Jul 20, 2026

Bronstein, Gewirtz & Grossman, LLC Encourages Nektar Therapeutics (NKTR) Shareholders to Inquire about Securities Investigation - ACCESS Newswire

Jul 20, 2026
pulisher
Jul 19, 2026

Enterprise value to EBIT forward of Nektar Therapeutics – BMV:NKTR - TradingView

Jul 19, 2026
pulisher
Jul 19, 2026

Nektar Therapeutics (NKTR) Stock Looks Above Fair Value Despite Its 7x Run - simplywall.st

Jul 19, 2026
pulisher
Jul 19, 2026

Enterprise value to EBITDA forward of Nektar Therapeutics – BMV:NKTR - TradingView

Jul 19, 2026
pulisher
Jul 18, 2026

Price to sales forward of Nektar Therapeutics – BMV:NKTR - TradingView

Jul 18, 2026
pulisher
Jul 18, 2026

Bronstein, Gewirtz & Grossman, LLC Is Investigating Nektar Therapeutics (NKTR) And Encourages Shareholders to Connect - ACCESS Newswire

Jul 18, 2026
pulisher
Jul 18, 2026

ETFs Investing in Nektar Therapeutics Stocks - TradingView

Jul 18, 2026
pulisher
Jul 18, 2026

Enterprise value to EBIT forward of Nektar Therapeutics – MUN:ITH0 - TradingView

Jul 18, 2026
pulisher
Jul 17, 2026

Bronstein, Gewirtz & Grossman, LLC Is Investigating Nektar Therapeutics (NKTR) And Encourages Investors to Connect - ACCESS Newswire

Jul 17, 2026
pulisher
Jul 16, 2026

2026-07-16 | Bronstein, Gewirtz & Grossman, LLC Is Investigating Nektar Therapeutics (NKTR) And Encourages Shareholders to Connect | NDAQ:NKTR | Press Release - Stockhouse

Jul 16, 2026
pulisher
Jul 16, 2026

Nektar Therapeutics (NKTR) Investigation: Bronstein, Gewirtz & Gr - The National Law Review

Jul 16, 2026
pulisher
Jul 15, 2026

Bronstein, Gewirtz & Grossman, LLC Encourages Nektar Therapeutics - The National Law Review

Jul 15, 2026
pulisher
Jul 14, 2026

BTIG Maintains Nektar Therapeutics(NKTR.US) With Buy Rating, Maintains Target Price $178 - 富途牛牛

Jul 14, 2026
pulisher
Jul 13, 2026

Q32 bounces back to claim study success for alopecia drug - BioPharma Dive

Jul 13, 2026
pulisher
Jul 12, 2026

Bronstein, Gewirtz & Grossman, LLC Encourages Nektar Therapeutics (NKTR) Stockholders to Inquire about Securities Investigation - ACCESS Newswire

Jul 12, 2026
pulisher
Jul 12, 2026

2026-07-12 | Bronstein, Gewirtz & Grossman, LLC Encourages Nektar Therapeutics (NKTR) Stockholders to Inquire about Securities Investigation | NDAQ:NKTR | Press Release - Stockhouse

Jul 12, 2026
pulisher
Jul 10, 2026

Does Nektar Therapeutics (NKTR) Straddling Russell Growth and Value Indexes Reveal a Conflicted Narrative? - Sahm

Jul 10, 2026
pulisher
Jul 10, 2026

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Nektar Therapeutics (NKTR) and Encourages Investors to Learn More About the Investigation - ACCESS Newswire

Jul 10, 2026
pulisher
Jul 07, 2026

Nektar Therapeutics (NKTR) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire

Jul 07, 2026
pulisher
Jul 07, 2026

Enterprise value to EBITDA forward of Nektar Therapeutics – LSE:0UNL - TradingView

Jul 07, 2026
pulisher
Jul 07, 2026

Analysts Offer Insights on Healthcare Companies: Pyxis Oncology (PYXS) and Nektar Therapeutics (NKTR) - The Globe and Mail

Jul 07, 2026
pulisher
Jul 06, 2026

Nektar Therapeutics (NKTR) Advances Autoimmune Pipeline, Is The Upside Already Priced In? - simplywall.st

Jul 06, 2026
pulisher
Jul 04, 2026

NKTR Stock Clocks Best Day In Over 2 Months As Investors Await Upcoming Clinical Data In Eczema - Stocktwits

Jul 04, 2026
pulisher
Jul 02, 2026

Insider Sell: Jonathan Zalevsky Sells Shares of Nektar Therapeutics (NKTR) - GuruFocus

Jul 02, 2026
pulisher
Jul 02, 2026

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Nektar Therapeutics (NKTR) and Encourages Stockholders to Learn More About the Investigation - ACCESS Newswire

Jul 02, 2026

Nektar Therapeutics (NKTR) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading
$91.09
price up icon 1.97%
$118.87
price up icon 1.02%
$34.72
price down icon 0.83%
$58.73
price down icon 0.17%
ONC ONC
$325.90
price up icon 0.00%
$278.40
price up icon 2.44%
大文字化:     |  ボリューム (24 時間):